临床试验/NCT02162251

NCT02162251已完成不适用

Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease

Eisai Co., Ltd.0 个研究点目标入组 3,482 人开始时间: 2013年6月1日最近更新: 2018年9月7日

适应症

干预措施

试验速览

阶段: 不适用
状态: 已完成
发起方: Eisai Co., Ltd.
入组人数: 3,482
主要终点: Investigations on adverse events and adverse drug reactions

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

To investigate the safety and effectiveness about administration of both donepezil hydrochloride and menatine hydrochloride in patients with Alzheimer's Disease in clinical practice.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

研究组 & 干预措施

E2020

干预措施: Donepezil Hydrochloride (Drug)

结局指标

主要结局

Investigations on adverse events and adverse drug reactions

时间窗: Up to 12 months

次要结局

Severity of dementia based on the Functional Assessment Staging Test (FAST)(Baseline, Month 3, Month 6, and Month 12)
Change From Baseline in the Mini-Mental State Examination (MMSE) Score(Baseline and Month 12)

研究者

发起方

Eisai Co., Ltd.

申办方类型

Industry

责任方

Sponsor

相似试验

已完成

不适用

Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Clinical Safety and Effectiveness in Patients With Alzheimer's DiseaseAlzheimer's Disease

NCT01251718Eisai Co., Ltd.894

未知

Unknown

Post-marketing surveillance of donepezil hydrochloride -Investigation of the clinical safety and effectiveness in patients with Alzheimer's DiseaseAlzheimer's Disease

JPRN-jRCT1080221997Eisai Co., Ltd.1,000

未知

Unknown

Post-marketing surveillance of donepezil hydrochloride Dementia with Lewy bodies/long-term administratioDementia with Lewy bodies

JPRN-jRCT1080222854Eisai Co., Ltd.500

未知

Unknown

Investigation of the safety and effectiveness of combination therapy of donepezil hydrochloride and memantine hydrochloride in patients with Alzheimer's DiseaseAlzheimer's Disease

JPRN-jRCT1080222139Eisai Co., Ltd.5,000

未知

Unknown

Investigation of the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practiceAlzheimer's Disease

JPRN-jRCT1080222138Eisai Co., Ltd.10,000